These results offer a preclinical proof for the administration of A2AR inhibitor on prophylactic experimental therapy of HNSCC and suggest that A2AR blockade can be a potential novel strategy for HNSCC immunotherapy. The gene discussed is ADORA2A; the disease is head and neck squamous cell carcinoma.